Dataset from A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects

This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine)
and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used
in combination with KALETRA (lopinavir/ritonavir) over 96 weeks